(Q38232124)

31 August 2017

title

Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact (English)

1 reference

31 August 2017

Suzanna M Tatarewicz

1

1 reference

31 August 2017

Daniel T Mytych

2

1 reference

31 August 2017

Marta Starcevic Manning

3

1 reference

31 August 2017

Steven J Swanson

4

1 reference

31 August 2017

Michael S Moxness

5

1 reference

31 August 2017

Narendra Chirmule

6

1 reference

31 August 2017

publication date

1 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

6

1 reference

31 August 2017

issue

11

1 reference

31 August 2017

page(s)

1509-1523

1 reference

Impact of product-related factors on immunogenicity of biotherapeutics

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Immunogenicity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

A survey of applications of biological products for drug interference of immunogenicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Thrombocytopenia caused by the development of antibodies to thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Immune-mediated adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Autoimmune Diseases Induced by TNF-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Preclinical and clinical safety of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Antigen-bearing dendritic cells regulate the diverse pattern of memory CD8 T-cell development in different tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Impact of anti-drug antibodies in preclinical pharmacokinetic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

The use of receiver operating characteristic curves in biomedical informatics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Elimination of antibodies to recombinant enzyme in Pompe's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Origin of murine B cell lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Immunoglobulin class switching

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Selective IgG subclass deficiency: quantification and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Measurement of anti-erythropoiesis-stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell aplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

The role of IgA and IgA Fc receptors as anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

What is a B-cell epitope?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

ElliPro: a new structure-based tool for the prediction of antibody epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Conformational B-cell epitope prediction on antigen protein structures: a review of current algorithms and comparison with common binding site prediction methods

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Reducing the immunogenicity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Prediction of residues in discontinuous B-cell epitopes using protein 3D structures

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Determination of protein-derived epitopes by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.14.114

21 January 2018

Identifiers

DOI

10.4155/BIO.14.114

1 reference

31 August 2017

1 reference